Tapering off benzodiazepines in long-term users: An economic evaluation

PharmacoEconomics

Volumn 24, Issue 7, 2006, Pages 683-694

  Oude Voshaar, Richard C ^a   Krabbe, Paul F M ^a   Gorgels, Wim J M J ^a   Adang, Eddy M M ^a   Van Balkom, Anton J L M ^b   Van De Lisdonk, Eloy H ^a   Zitman, Frans G ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE;

ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DEPENDENCE; DRUG HYPERSENSITIVITY; DRUG USE; DRUG WITHDRAWAL; FALLING; FOLLOW UP; HEALTH CARE COST; HEALTH SERVICE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOCIETY; TRAFFIC ACCIDENT;

BENZODIAZEPINES; COGNITIVE THERAPY; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NETHERLANDS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 33745712618     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624070-00007     Document Type: Article

References (52)

1. Taylor S, McCracken CFM, Wilson KCM. Extent and appropriateness of benzodiazepine use. Br J Psychiatry 1998; 173: 433-8
2. Tu K, Mamdani MM, Hux JE, et al. Progressive trends in the prevalence of benzodiazepine prescribing in older people in Ontario, Canada. J Am Geriatr Soc 2001; 49: 1341-5
3. Zandstra SM, Führer JW, Van de Lisdonk EH, et al. Different study criteria affect the prevalence of benzodiazepine use. Soc Psychiatry Psychiatr Epidemiol 2002; 37 (3): 139-44
4. USA Food and Drug Administration. Prescribing of minor tranquillizers. FDA Drug Bull 1980; 10: 2-3
5. Committee on the Review of Medicines. Systematic review of the benzodiazepines. BMJ 1980; 1: 910-2
6. Knuistingh-Neven A, de Graaff WJ, Lucassen PLBJ, et al. NHG-standaard Slapeloosheid en slaapmiddelen. Huisarts Wet 1992; 35: 212-9
7. Neomagus GJH, Terluin B, Aulbers LPJ, et al. NHG-standaard Angststoornissen. Huisarts Wet 1997; 40: 167-75
8. Ashton H. Guidelines for the rational use of benzodiazepines: when and what to use. Drugs 1994; 48: 25-40
9. Kan CC, Breteler MH, Zitman FG. High prevalence of benzodiazepine dependence in out-patient users, based on the DSM-III-R and ICD-10 criteria. Acta Psychiatr Scand 1997; 96: 85-93
10. Rummans TA, Davis LJ, Morse RM, et al. Learning and memory impairment in older, detoxified, benzodiazepine-dependent patients. Mayo Clin Proc 1993; 68: 731-7
11. Tata PR, Rollings J, Collins M, et al. Lack of cognitive recovery following withdrawal from long-term benzodiazepine use. Psychol Med 1994; 24: 203-13
12. Paterniti S, Dufouil C, Alpérovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the epidemiology of vascular aging study. J Clin Psychopharmacol 2002; 22: 285-93
13. Rickels K, Lucki I, Schweizer E, et al. Psychomotor performance of long-term benzodiazepine users before, during, and after benzodiazepine discontinuation. J Clin Psychopharmacol 1999; 19: 107-13
14. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis. I: psychotropic drugs. J Am Geriatr Soc 1999; 47: 30-9
15. Hemmelgarn B, Suissa S, Huang A, et al. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 1997; 278: 27-31
16. Piepenbrink JF, editor. College voor zorgverzekeringen. Use of benzodiazepines 1993-1998 [in German]. Amstelveen: Geneesmiddelen Informatie Project (GIP-signaal), 2000
17. Herings RMC. Drugs as determinants of accidents [in German]. Utrecht: Faculteit Pharmacie, 1994
18. Panneman MJ, Goettsch WG, Kramarz P, et al. The costs of benzodiazepine-associated hospital-treated fall injuries in the EU: a Pharmo study. Drugs Aging 2003; 20 (11): 833-9
19. Cormack MA, Howells E. Factors linked to the prescribing of benzodiazepines by general practice principals and trainees. Fam Pract 1992; 9 (4): 466-71
20. Holton A, Riley P, Tyrer P. Factors predicting long-term outcome after chronic benzodiazepine therapy. J Affect Disord 1992; 24 (4): 245-52
21. Burke KC, Meek WJ, Krych R, et al. Medical services use by patients before and after detoxification from benzodiazepine dependence. Psychiatr Serv 1995; 46 (2): 157-60
22. Bashir K, King M, Ashworth M. Controlled evaluation of brief intervention by general practitioners to reduce chronic use of benzodiazepines. Br J Gen Pract 1994; 44 (386): 408-12
23. Morgan JD, Wright DJ, Chrystyn H. Pharmacoeconomic evaluation of a patient education letter aimed at reducing long-term prescribing of benzodiazepines. Pharm World Sci 2002; 24 (6): 231-5
24. Ashton H. Benzodiazepine withdrawal: outcome in 50 patients. Br J Addict 1987; 82 (6): 665-71
25. Rickels K, Case WG, Schweizer E, et al. Long-term benzodiazepine users 3 years after participation in a discontinuation program. Am J Psychiatry 1991; 148 (6): 757-61
26. Gorgels WJ, Oude Voshaar RC, Mol AJ, et al. Discontinuation of long-term benzodiazepine use by sending a letter to users in family practice: a prospective controlled intervention study. Drug Alcohol Depend 2005; 78 (1): 49-56
27. Oude Voshaar RC, Gorgels WJ, Mol AJ, et al. Tapering off long-term benzodiazepine use with or without simultaneous group cognitive-behavioural therapy: three-condition randomised controlled trial. Br J Psychiatry 2003; 182: 498-502
28. Oude Voshaar RC, Gorgels WJMJ, Mol AJJ, et al. Long-term outcome of three-condition, usual care controlled controlled, randomised benzodiazepine discontinuation study. Br J Psychiatry 2006; 188: 188-9
29. Furlong WJ, Feeny DH, Torrance GW, et al. Multiplicative multi-attribute utility function for the health utility index mark 3 (HUI3) system: a technical report. Working paper 98-11. Toronto (ON): McMaster University Centre for Health Economics and Policy Analysis, 1998
30. Furlong WJ, Feeny DH, Torrance GW, et al. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001; 33: 375-84
31. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473-83
32. Van der Zee KI, Snaderman R. Measuring general health status with the RAND-36. Users manual [in German]. Groningen: Nothern Center of Health Care Research, 1993
33. WHO Collaborating Centre for Drugs Statistics Methodology. Guidelines ATC classification and DDD assignment. 1st ed. Oslo: WHO/NCM, 1996
34. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Handleiding voor kostenonderzoek, methoden en richtlijnprijzen voor economische evaluaties in de gezondheidszorg. Amstelveen: College voor zorgverzekeringen, 2000
35. Commissie Farmaceutische Hulp van het College voor zorgverzekekeringen (CVZ). Farmacotherapeutische kompas. Amstelveen: CVZ, 2002: 53-66, 69-81
36. CBS statistieken, bron statline [online]. Available from URL: http://www.cbs.nl [Accessed 2002 Aug]
37. Rodrigo EK, King MB, Williams P. Health of long-term benzodiazepine users. BMJ 1988; 296: 603-6
38. Simpson RJ, Power KG, Wallace LA. Controlled comparison of the characteristics of long-term benzodiazepine users in general practice. Br J Gen Pract 1990; 40: 22-6
39. Van Hulten R, Teeuw KB, Bakker A, et al. Health-related quality of life in current benzodiazepine users and general population controls. In: Blue boy - why not? Studies on benzodiazepine use in a Dutch community [dissertation]. Utrecht: Rolf van Hulten & Stichting Kalamiteit, 1998: 73-88
40. Gray A, Marshall M, Lockwood A, et al. Poblems in conducting economic evaluations alongside clinical trials. Br J Psychiatry 1997; 170: 47-52
41. Zitman FG, Couvee JE. Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off. Report on behalf of the Dutch Chronic Benzodiazepine Working Group. Br J Psychiatry 2001; 178: 317-24
42. Schweizer E, Rickels K, Case WG, et al. Long-term therapeutic use of benzodiazepines: II. Effects of gradual taper. Arch Gen Psychiatry 1990; 47: 908-15
43. Schweizer E, Rickels K, De Martinis N, et al. The effect of personality on withdrawal severity and taper outcome in benzodiazepine dependent patients. Psychol Med 1998; 28: 713-20
44. Rickels K, DeMartinis N, Garcia-Espana F, et al. Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. Am J Psychiatry 2000; 157: 1973-9
45. Higgitt A, Golombok S, Fonagy P, et al. Group treatment of benzodiazepine dependence. Br J Addict 1987; 82: 517-32
46. Sanchez-Craig M, Cappell H, Busto U, et al. Cognitive-behavioural treatment for benzodiazepine dependence: a comparison of gradual versus abrupt cessation of drug intake. Br J Addict 1987; 82: 1317-27
47. Otto MW, Pollack MH, Sachs GS, et al. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry 1993; 150: 1485-90
48. Elsesser K, Sartory G, Maurer J. The efficacy of complaints management training in facilitating benzodiazepine withdrawal. Behav Res Ther 1996; 34: 149-56
49. Charney DA, Paraherakis AM, Gill KJ. The treatment of sedative-hypnotic dependence: evaluating clinical predictors of outcome. J Clin Psychiatry 2000; 61: 190-5
50. Baillargeon L, Landreville P, Verreault R, et al. Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial. CMAJ 2003; 169 (10): 1015-20
51. Morin CM, Bastien C, Guay B, et al. Randomized clinical trial of supervised tapering and cognitive behaviour therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia. Am J Psychiatry 2004; 161: 332-42
52. Couvée JE, Timmermans EAY, Zitman FG. The long-term outcome of a benzodiazepine discontinuation programme in depressed outpatients. J Affect Disord 2002; 70 (2): 133-41